Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial [Original Articles]

Conclusions: Adalimumab reduced key markers of inflammation including glycoprotein acetylation compared with phototherapy with no effect on glucose metabolism and vascular inflammation, and potential adverse effects on high-density lipoprotein. Glycoprotein acetylation improvement may partially explain the beneficial effects of adalimumab seen in observational studies. Larger studies with more detailed phenotyping of vascular disease should assess the comparative differences in the effects of adalimumab and phototherapy seen in our study. Clinical Trial Registration : URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01866592 and NCT01553058.

http://circimaging.ahajournals.org/cgi/content/short/11/6/e007394?rss=1

Source: Circulation: Cardiovascular Imaging - May 18, 2018 Category: Radiology Authors: Mehta, N. N., Shin, D. B., Joshi, A. A., Dey, A. K., Armstrong, A. W., Duffin, K. C., Fuxench, Z. C., Harrington, C. L., Hubbard, R. A., Kalb, R. E., Menter, A., Rader, D. J., Reilly, M. P., Simpson, E. L., Takeshita, J., Torigian, D. A., Werner, T. J., T Tags: Biomarkers, Nuclear Cardiology and PET, Vascular Disease Original Articles Source Type: research